The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Implementing bispecific antibodies in triple-class-exposed multiple myeloma
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center and University of Miami, Miami, FL, discusses key themes from a session he chaired at IMS 2026 on implementing bispecific antibodies for triple-class-exposed patients with relapsed/refractory (R/R) multiple myeloma. He highlights real-world evidence supporting the efficacy and safety of these therapies compared with registrational trials, practical considerations for outpatient step-up dosing and treating higher-risk patients, and differences in access and implementation between the United States and Europe. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
